Skip to Content

Aliqopa Approval History

FDA Approved: Yes (First approved September 14, 2017)
Brand name: Aliqopa
Generic name: copanlisib
Dosage form: Injection
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Follicular Lymphoma

Aliqopa (copanlisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).

Development History and FDA Approval Process for Aliqopa

DateArticle
Sep 14, 2017Approval FDA Approves Aliqopa (copanlisib) for Adults with Relapsed Follicular Lymphoma
May 17, 2017FDA Grants Bayer Priority Review for Investigational Compound Copanlisib in Follicular Lymphoma
Mar 31, 2017Phase II Data Show Bayer's Investigational Compound Copanlisib Achieved Durable Tumor Response in Indolent Non-Hodgkin's Lymphoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide